VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has raised €77.8 million through a private placement via an accelerated bookbuilding procedure announced on Wednesday 28 March 2012 after the market closed. read more
PharmaNeuroBoost (PNB) announced today that it obtained approval from the Belgian Authorities and from the Central Ethics Committee to initiate a Proof-of-Concept study in patients with chronic Schizophrenia. The objectives of this study are to evaluate the effect of PNB02, PNB’s second product in development, on functional Magnetic Resonance Imaging (MRI) of the brain and to evaluate the clinical effect of PNB02 treatment in patients with chronic Schizophrenia who are suffering from residual symptoms. read more
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces the launch of a private placement of new ordinary shares to raise up to 10% of the current number of outstanding shares (i.e. 3,244,675 new shares). The Board of Directors has resolved to disapply the preferential subscription rights of existing shareholders in connection with the intended capital increase, which will take place within the limits of the authorized share capital in accordance with article 604 of the Belgian Company Code. read more
Promethera Biosciences, the Belgian cell therapy company operating in the field of liver disease, completed today an exceptional fundraising round that generated EUR 23.6 million, including EUR 17 million in capital. Among the new investors are the venture arms of pharmaceutical industry leaders Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI and Belgian venture capital fund SambrInvest. This Series-B fundraising has been successful thanks to the major achievements made by Promethera Biosciences since its Series-A fundraising in 2009. Most outstanding is the GMP accreditation following the successful transfer and scaling up of the production process developed at Université catholique de Louvain (UCL) into a larger-scale pharmaceutical operation. Meanwhile, the company has been granted authorisations from the respective agencies to start its phase I/II clinical study in Belgium and the UK for its innovative cell therapeutic product HepaStem which may hold a cure for liver diseases and offer a breakthrough technology for repairing severe liver defects. read more
ACTMOST project to help SMEs access top-level expertise will prove influential in Europe, says co-ordinator Hugo Thienpont. read more
Biogazelle, the real-time PCR data analysis company, built upon a decade of experience in real-time PCR experiment design, assay development and data-analysis, today announced the appointment of Kris Vanhercke as its new Chief Operating Officer. read more
The Board of Parents program hosts its delegates at the flagship laboratory in Niel, Belgium read more